LX2006

In 2018, Ron Crystal, Professor, and Chairman of the Department of Genetic Medicine Department at Weill Cornell Medicine founded Lexeo with National Institutes of Health small business grants. In January 2021, the company raised an $85 million Series A to develop 18 preclinical and clinical programs, including a lead program for cardiomyopathy in F A. In March 2021, LEXEO announced the completion of a license of all intellectual property rights and pre-clinical data associated with Adverum Biotechnologies’ investigational Friedreich’s ataxia program. In February 2022, Lexeo announced the approval of their Investigational New Drug (IND) application for LX2006, an AAV-based gene therapy candidate for Friedreich’s Ataxia cardiomyopathy. The phase 1 study is expected to begin later in 2022.